prothymosin alpha comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-29. Numbers and descriptions here follow the published literature rather than marketing material.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
=== Steps of the urea cycle === Carbamoyl phosphate is converted to citrulline. With catalysis by ornithine transcarbamylase, the carbamoyl phosphate group is donated to ornithine and releases a phosphate group. A condensation reaction occurs between the amino group of aspartate and the carbonyl group of citrulline to form argininosuccinate. This reaction is ATP dependent and is catalyzed by argininosuccinate synthetase. Argininosuccinate undergoes cleavage by argininosuccinase to form arginine and fumarate. Arginine is cleaved by arginase to form urea and ornithine. The ornithine is then transported back to the mitochondria to begin the urea cycle again.
Dried and salted cod, sometimes referred to as salt cod or saltfish or salt dolly, is cod which has been preserved by drying after salting. Cod which has been dried without the addition of salt is stockfish. Salt cod was long a major export of the North Atlantic region, and has become an ingredient of many cuisines around the Atlantic and in the Mediterranean. Dried and salted cod has been produced for over 500 years in Newfoundland, Iceland, and the Faroe Islands. It is also produced in Norway, where it is called klippfisk, literally "cliff-fish". Traditionally, it was dried outdoors by the wind and sun, often on cliffs and other bare rock-faces. Today, klippfisk is usually dried indoors with the aid of electric heaters. But in western and northern Norway fish is still dried outdoors, mainly for export to southern Europe markets.
=== Capsule === Certain strains of S. haemolyticus are capable of producing a capsular polysaccharide (CP). S. haemolyticus strain JCSC1435 contains a capsule operon located within the “oriC environ”. This operon contains 13 ORFs in a 14,652-bp region and is referred to as the capsh locus. The first seven genes of capsh (capAsh through capGsh) are homologous to the S. aureus cap5 or cap8 locus. However, capH through capM are unique to S. haemolyticus, and this region encodes enzymes for a unique trideoxy sugar residue that is N-acylated by aspartic acid. CP production is influenced by culture medium and growth phase. Cultivation in tryptic soy broth (TSB)], TSB with 1% glucose, brain heart infusion broth, or Columbia broth with 2% NaCl favors the production of CP; cultivation on Columbia salt agar plates is suboptimal. Only trace amounts of CP are generated before the end of exponential phase, and the maximal rate of CP production does not occur until early stationary phase. CP is considered a virulence factor because it provides resistance against complement-mediated polymorphonuclear neutrophil phagocytosis.
Sources: en.wikipedia.org
=== Generic names === Nicergoline is the generic name of the drug and its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française.
Action Game – Half-Life 2 Animation – Half-Life 2 Art Direction – Half-Life 2 Audio Achievement – Call of Duty: Finest Hour Best Game – Half-Life 2 Children's – Donkey Konga GameCube – Prince of Persia: Warrior Within Handheld – Colin McRae Rally 2005 Mobile Game – BlueTooth BiPlanes Online Multiplayer – Half-Life 2 Original Music – Hitman: Contracts Originality – SingStar/Singstar Party PC – Half-Life 2 PS2 – Burnout 3: Takedown Racing – Burnout 3: Takedown Sports – Pro Evolution Soccer 4 Sunday Times Reader Award for Games – Football Manager 2005 Technical Direction – Burnout 3: Takedown Xbox – Halo 2 Special Award (Games) – Sam Houser & Leslie Benzies
== Franchises == TGI Fridays is a franchising operation, with franchisees owning most of the outlets. In 2011, the largest franchisee was The Briad Group in New Jersey, which ran 72 restaurants in six states. Briad sold its franchises in 2020. Whitbread PLC, with 45 locations in the United Kingdom, was a major international franchisee until 2007. On January 17, 2007, Whitbread sold operating rights to all 45 restaurants back to TGI Fridays UK Limited (a consortium consisting of Carlson Restaurants Worldwide Inc. and ABN Amro Capital) thus exiting a partnership formed in 1986. TGI Fridays has also been used as a restaurant for hotels run by Country Inns & Suites by Carlson brand. On 18 September 2024, Hostmore PLC entered administration; all UK restaurant locations were offered for sale. 51 sites were sold the following month, while a further 35 closed.
Sources: en.wikipedia.org
== Medical uses == In 1970, Eckelman and Richards presented the first "kit" containing all the ingredients required to release the 99mTc, "milked" from the generator, in the chemical form to be administered to the patient. Technetium-99m is used in 20 million diagnostic nuclear medical procedures every year. Approximately 85% of diagnostic imaging procedures in nuclear medicine use this isotope as radioactive tracer. Klaus Schwochau's book Technetium lists 31 radiopharmaceuticals based on 99mTc for imaging and functional studies of the brain, myocardium, thyroid, lungs, liver, gallbladder, kidneys, skeleton, blood, and tumors. A more recent review is also available. Depending on the procedure, the 99mTc is tagged (or bound to) a pharmaceutical that transports it to its required location. For example, when 99mTc is chemically bound to exametazime (HMPAO), the drug is able to cross the blood–brain barrier and flow through the vessels in the brain for cerebral blood-flow imaging. This combination is also used for labeling white blood cells (99mTc labeled WBC) to visualize sites of infection. 99mTc sestamibi is used for myocardial perfusion imaging, which shows how well the blood flows through the heart. Imaging to measure renal function is done by attaching 99mTc to mercaptoacetyl triglycine (MAG3); this procedure is known as a MAG3 scan.
=== Quantum tunneling === Quantum mechanics, however, allows the alpha particle to escape via quantum tunneling. The quantum tunneling theory of alpha decay, independently developed by George Gamow and by Ronald Wilfred Gurney and Edward Condon in 1928, was hailed as a very striking confirmation of quantum theory. Essentially, the alpha particle escapes from the nucleus not by acquiring enough energy to pass over the wall confining it, but by tunneling through the wall. Gurney and Condon made the following observation in their paper on it:
In Burma (Myanmar), the sphinx-like statue, with a human head and two lion hindquarters, is known as Manussiha (manuthiha). It is depicted on the corners of Buddhist stupas, and its legends tell how it was created by Buddhist monks to protect a new-born royal baby from being devoured by ogresses. Nora Nair, Norasingha and Thep Norasingha are three of the names under which the "sphinx" is known in Thailand. They are depicted as upright walking beings with the lower body of a lion or deer, and the upper body of a human. Often they are found as female-male pairs. Here, too, the sphinx serves a protective function. It also is enumerated among the mythological creatures that inhabit the ranges of the sacred mountain Himapan.
== Epidemiology == Leiomyosarcomas are rare. Sarcomas combined account for less than 1% of cancer diagnoses, and leiomyosarcoma accounts for around 10% of sarcoma diagnoses. Around 63% of uterine sarcomas, 20% of abdominal sarcomas, and 15% of sarcomas of the arms and legs are leiomyosarcomas. Non-uterine leiomyosarcoma is around 40% more common in women than in men. The disease generally affects older adults with the average person diagnosed around age 60. Uterine leiomyosarcoma most commonly impacts women in perimenopause, with an average age of diagnosis at 57.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.